This is the talk page for discussing improvements to the CureVac article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
![]() | Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
![]() | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
![]() | The Wikimedia Foundation's Terms of Use require that editors disclose their "employer, client, and affiliation" with respect to any paid contribution; see WP:PAID. For advice about reviewing paid contributions, see WP:COIRESPONSE.
|
![]() | This edit request by an editor with a conflict of interest has now been answered. |
I would like to request the following change: CureVac has entered into a collaboration with Eli Lilly and Company in October 2017. This could be included in the list of partners at the beginning of the entry as well as in the history part. Neutral sources are e.g. https://endpts.com/eli-lilly-is-making-a-1-8b-leap-into-the-mrna-field-targeting-next-gen-cancer-vaccines/ and https://www.fiercebiotech.com/biotech/lilly-curevac-pen-1-8b-mrna-cancer-vaccine-deal Thank you for reviewing, --VerenaLauterbach CureVacAG (talk) 12:49, 8 May 2018 (UTC)
When ready to proceed with your response to point No. 1 above, kindly change the request edit template to read from ans=yes to ans=no. Thank you! .spintendo⋅⋅) 13:42, 8 May 2018 (UTC)
References
Implemented The Lilly information was added to where you indicated, along with the reference. .spintendo⋅⋅) 18:22, 8 May 2018 (UTC)
![]() | Part of an edit requested by an editor with a conflict of interest has been implemented. Please see below for more information. |
I request the following edit: Please change
In September 2015, CureVac announced it would be opening a United States hub in Cambridge, Massachusetts.[18]
to
In September 2015, CureVac announced it would be opening a United States hub in Cambridge, Massachusetts[18] which moved to Boston later the same year.[1]
--VerenaLauterbach CureVacAG (talk) 12:11, 17 May 2018 (UTC)
References
Implemented .spintendo⋅⋅) 17:17, 17 May 2018 (UTC)
![]() | Part of an edit requested by an editor with a conflict of interest has been implemented. Please see below for additional information. |
I request the following edit: Please change
In 2016 CureVac will start the construction of an industrial scale production facility with a capacity of 30 million doses per year.[7]
to
In 2016, CureVac has started the construction of an industrial scale production facility with a capacity of 30 million doses per year.[1]
References
Thank you in advance, --VerenaLauterbach CureVacAG (talk) 09:01, 18 May 2018 (UTC)
![]() | Part of an edit requested by an editor with a conflict of interest has been implemented. Please see below for additional information. |
I request the following edit: Please change
Since inception, CureVac had received approximately $330 million (€300 million) in equity investments.[3]
to
Since inception, CureVac had received approximately $360 million (€300 million) in equity investments and has a valuation of $1.65 billion (status October 2017)[1] and thus is classified as a Unicorn (finance).
Thank you, --VerenaLauterbach CureVacAG (talk) 09:26, 18 May 2018 (UTC)
![]() | Part of an edit requested by an editor with a conflict of interest has been implemented. Please see below for additional information. |
Since the link of source no. 18 ("Sequence Engineered mRNA Without Chemical Nucleoside Modifications...") does not work any more, I suggest to replace it with the current link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817881/ Thanks, --VerenaLauterbach CureVacAG (talk) 11:33, 23 May 2018 (UTC)
![]() | Part of an edit requested by an editor with a conflict of interest has been implemented. Please see below for additional information. |
Since the source of the sentence "In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA for medical purposes" actually does not account for this information, I suggest to change it to the following: https://www.pharmaceutical-technology.com/projects/curevac-gmp-iv-production-facility-tubingen/ This source, however, does not verify that it was the "first worldwide", so this part probably should be deleted from the sentence. Thanks, --VerenaLauterbach CureVacAG (talk) 12:29, 23 May 2018 (UTC)
![]() | This edit request by an editor with a conflict of interest has now been answered. |
Thank you for reviewing and the feedback which makes perfectly sense as well as for the directions concerning the editing process.
I have one more request concerning the refimprove template: As far as I can see, all details in the article now have citations from reliable sources; the only source that does not quite verify the content of the article is source no. 16: Since the technology section of the article now only consists of one sentence which, moreover, does not include up-to-date facts and figues (numbers outdated, trial finished, at the same time several other trials in progress), I would suggest to delete this parapraph. Afterwards, I ask to remove the refimprove template and to reconsider the stub grading of the article. If there are other concerns regarding the article, please let me know and I will do my best to help improving it.
Is it okay if I set links to other articles myself (e.g. change vaccines to vaccines, Nature Biotechnology to Nature Biotechnology...)?
Thank you in advance, --VerenaLauterbach CureVacAG (talk) 08:30, 24 May 2018 (UTC)
Implemented
![]() | This edit request by an editor with a conflict of interest has now been answered. |
I would like to request that a management change be incuded in the text or the box: New CEO is Daniel L. Menichella, formerly Chief Business Officer of the AG and Chief Executive Officer of the Inc. He replaces founder and former CEO Ingmar Hoerr, PhD, who is now Chairman of the Supervisory Board. You can find sources on the website (http://www.curevac.com/news/curevac-announces-new-management-structure/) or e.g. on this news site (https://www.fiercepharma.com/vaccines/news-note-sinovac-drama-sequel-flu-vaccine-and-more?utm_source=internal&utm_medium=rss).
Thank you for reviewing, --VerenaLauterbach CureVacAG (talk) 07:46, 21 June 2018 (UTC)
This page is not a clean recounting of Curevac's story which is much more complicated and interesting than what is portrayed here with some significant ups and downs. The history of this company, founded in 2000, bizarrely starts in 2013. I have retagged the page is this is not a WP article. Jytdog (talk) 15:46, 21 June 2018 (UTC)
![]() | This edit request by an editor with a conflict of interest has now been answered. |
The number of employees has changed and is currently at about 400 (same source as before). Could somebody please adapt this change?
Thank you, --VerenaLauterbach CureVacAG (talk) 07:31, 9 August 2018 (UTC)
Done spintendo 09:44, 9 August 2018 (UTC)
I don't know policy on this one, but I'm personally not enthused about the use of a prominent image containing a slogan beholden to ®, universal symbol of conspicuously lawyered up. — MaxEnt 17:59, 5 May 2021 (UTC)
I gave this article a quick skim and I really don't see a lot of content here where one would question impartiality of a main contributor. Is this flag still required?
I made one quick change to the lead to push the aspirational rah-rah-rah sentence down to the top of the second paragraph, with improved continuity.
The only sore thumb on quick inspection was overplaying the Trumpian scuttlebutt.
On 11 March 2020, it was reported that CureVac AG's CEO Daniel Menichella was no longer the company's CEO, having been replaced by company founder Ingmar Hoerr. Menichella was reported to have met U.S. President Donald Trump on 2 March.[1][2]
- ^ "Was it something he said? Biotech CEO who met Trump this month exits without a word". FierceBiotech. Retrieved 15 March 2020.
- ^ "Germany and US wrestle over coronavirus vaccine: report". Deutsche Welle. Retrieved 15 March 2020.
The paragraph continues with the core allegation that Trump offered a special deal. That part deserves entirely separate consideration. I myself have no immediate strong objection, but I can imagine another editor suggesting we nix that as well.
Those sentences read as innuendo about innuendo (my least favourite double down) and then there's the sourcing.
"Was it something he said?" passes the universal smell test for journalist fishing expeditions.
"Am I just saying?" smugs Tucker Carlson. "You be the judge." Also, could this be a legitimate, solid source? Asking for a friend.
Finally, I don't see the point in the context of this article to link sordid speculation about the timing of Menichella's replacement with the Trumpian scuttlebutt.
With this one deletion I would consider remove the conflict of interest flag at the top of the article, useless it's an ongoing concern. — MaxEnt 18:26, 5 May 2021 (UTC)
With this edit I'm somewhat contradicting my sentiment from my previous topic.
There is something fishy about this prominent list of "collaborations" indistinguishable from ordinary business relationships.
It's the kind of thing a motivate partisan would know how to pull together, where a random 3rd party editor would never sew such a vague, nondescript quilt.
CureVac has entered into various collaborations with organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline, Coalition for Epidemic Preparedness Innovations, the International AIDS Vaccine Initiative, and the government of Germany.
— MaxEnt 18:35, 5 May 2021 (UTC)
Hi, I previously edited the second paragraph of the lead section as it appeared to be some sort of translation that wasn't very great. Upon further reading I have noticed that what is said in this paragraph is repeated in a section dedicated to COVID-19. I propose that the second paragraph of the lead section is deleted and replaced with information that is more relevant to the company and what they do.
Thanks in advance Danwordy (talk) 15:52, 17 August 2023 (UTC)